Kelly Lawrence W & Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Kelly Lawrence W & Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-13	Closed	-$2K	–	179
2022 Q1	$2K	Hold	13	–	–	﹤0.01%	157
2021 Q4	$2K	Hold	13	–	–	﹤0.01%	166
2021 Q3	$2K	Hold	13	–	–	﹤0.01%	156
2021 Q2	$2K	Buy	+13	New	+$2.25K	﹤0.01%	156

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Kelly Lawrence W & Associates's JAZZ Position: Q2 2022 in Review

Kelly Lawrence W & Associates sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2022, closing a stake of 13 shares — an estimated $2K sold.

Kelly Lawrence W & Associates first reported a position in JAZZ in Q2 2021 and held it in 4 quarters. The position peaked at $2K in Q1 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q2 2022.

Kelly Lawrence W & Associates reported no remaining Jazz Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Kelly Lawrence W & Associates sold 13 Jazz Pharmaceuticals shares in Q2 2022, an estimated $2K.
Kelly Lawrence W & Associates first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 4 quarters.
Kelly Lawrence W & Associates's Jazz Pharmaceuticals position peaked at $2K in Q1 2022.
468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2022.

Based on Kelly Lawrence W & Associates's 13F filing for Q2 2022, filed 15 Aug 2022.